Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Russian Extreme Hypertriglyceridemia Registry

Russian Extreme Hypertriglyceridemia Registry (REGGI)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The REGGI registry is a prospective, multicenter observational registry in Russia designed to collect data on patients with extreme hypertriglyceridemia (triglyceride levels ≥10 mmol/L). The registry aims to describe the clinical, demographic, and molecular-genetic characteristics of patients, as well as current diagnostic approaches and treatment patterns in real-world practice. The collected data may inform future research and support improvements in patient care.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients with extreme hypertriglyceridemia (triglyceride levels ≥10 mmol/L), confirmed by at least two independent measurements. - Written willing to sign a consent form from the patient or legal guardian. - No age restrictions. Who Should NOT Join This Trial: - Patients whose extreme hypertriglyceridemia is caused by alcohol abuse, uncontrolled diabetes, or other medical conditions, unless extreme hypertriglyceridemia is confirmed after controlling the underlying condition. - Lack of willing to sign a consent form. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients with extreme hypertriglyceridemia (triglyceride levels ≥10 mmol/L), confirmed by at least two independent measurements. * Written informed consent from the patient or legal guardian. * No age restrictions. Exclusion Criteria: * Patients whose extreme hypertriglyceridemia is caused by alcohol abuse, uncontrolled diabetes, or other medical conditions, unless extreme hypertriglyceridemia is confirmed after controlling the underlying condition. * Lack of informed consent.

Locations (6)

Astrakhan State Medical University
Astrakhan, Russia
Chelyabinsk State Medical Academy
Chelyabinsk, Russia
Kaluga City Clinical Hospital No. 5
Kaluga, Russia
State Medical University
Kazan', Russia
National Medical Research Center of Cardiology Named after Academician E.I. Chazov
Moscow, Russia
Research Centre for Medical Genetics
Moscow, Russia